In addition, serum exosomal GGT1 can be used as a marker for the clinical features of advanced renal carcinoma [12], and a similar pattern was observed in prostate cancer, where serum exosomal GGT1 activity was significantly greater in malignant patients than in patients with benign hyperplasia [13]. This evidence concerns the gene GGT1 and prostate cancer.